$1.12
0.087.69%
al cierre: Nov 18, 4:00 PM EST
$1.12
0.07527.23%
Premercado: 4:01 AM EST
RenovoRx (RNXT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.07 | $-0.05 | -40.0 % |
| Q2 | Aug 12, 2026 | $-0.05 | $-0.08 | 37.5 % |
| Q1 | May 14, 2026 | $-0.08 | $-0.08 | 0.00 % |
| Q4 | Mar 30, 2026 | $-0.08 | $-0.08 | 0.00 % |
Quarterly Revenue (Billions)
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $1.07M | $1.06M | 0.41 % |
| Q2 | Aug 12, 2026 | $909.00K | $709.00K | 28.2 % |
| Q1 | May 14, 2026 | $563.00K | $470.60K | 19.6 % |
| Q4 | Mar 30, 2026 | $238.00K | $451.85K | -47.3 % |
RenovoRx (RNXT) publicó su última previsión de noviembre 5, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $3.75M - $4.25M para el período.
En comparación con la previsión anterior, RenovoRx mantenido redujo su previsión de ingresos desde un rango anterior de $3.75M - $4.25M.
RenovoRx ha emitido 3 actualizaciones de orientación entre el mayo 14, 2026 y el noviembre 5, 2026. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.05 | $-0.08 | $-0.08 | $-0.08 |
| Actual | $-0.07 | $-0.05 | $-0.08 | $-0.08 |
| Surprise | -40.0% | +37.5% | 0.00% | 0.00% |
| Revenue | ||||
| Estimate | $1.1M | $709000 | $470600 | $451850 |
| Actual | $1.1M | $909000 | $563000 | $238000 |
| Surprise | +0.41% | +28.2% | +19.6% | -47.3% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.07 | $-0.05 | $-0.06 | $-0.05 |
| Revenue | ||||
| Consensus | $1.3M | $1.4M | — | — |
